Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients : A multicentric real-life experience
Copyright © 2022 Iula, De Novellis, Trastulli, Della Pepa, Fontana, Carobene, Di Perna, D’Ambrosio, Romano, Leone, De Fazio, Fiumarella, Gaeta, Marafioti, Barbato, Palmieri, Rocco, Serio, Califano, Pane, Ferrara, Giudice, Selleri and Catalano..
Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we enrolled 28 MM patients treated in four Hematology units of Campania region, Italy, who received a median of six treatment lines prior to belantamab-mafodotin. The overall response rate (ORR) was 40% (complete remission, CR, 11%; very good partial remission, VGPR, 11%; and partial remission, PR, 18%), with a median progression-free survival (PFS) and overall survival (OS) of 3 and 8 months, respectively. One of the most frequent drug-related adverse events was keratopathy observed in nine (32%) patients, leading to therapy discontinuation in only three (11%) of them. Moreover, 22 out of 28 total patients who were treated with at least two administrations achieved an ORR of 50% (CR, 14%; VGPR, 14%; and PR, 22%) with a median PFS and OS of 5 and 11 months, respectively. In conclusion, our multicentric study confirmed efficacy and safety of belantamab-mafodotin in triple-refractory MM patients even in the real-life setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 12(2022) vom: 16., Seite 1026251 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Iula, Rossella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-BCMA |
|---|
| Anmerkungen: |
Date Revised 03.12.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2022.1026251 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349700826 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349700826 | ||
| 003 | DE-627 | ||
| 005 | 20231226205638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2022.1026251 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349700826 | ||
| 035 | |a (NLM)36457484 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Iula, Rossella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients |b A multicentric real-life experience |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Iula, De Novellis, Trastulli, Della Pepa, Fontana, Carobene, Di Perna, D’Ambrosio, Romano, Leone, De Fazio, Fiumarella, Gaeta, Marafioti, Barbato, Palmieri, Rocco, Serio, Califano, Pane, Ferrara, Giudice, Selleri and Catalano. | ||
| 520 | |a Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we enrolled 28 MM patients treated in four Hematology units of Campania region, Italy, who received a median of six treatment lines prior to belantamab-mafodotin. The overall response rate (ORR) was 40% (complete remission, CR, 11%; very good partial remission, VGPR, 11%; and partial remission, PR, 18%), with a median progression-free survival (PFS) and overall survival (OS) of 3 and 8 months, respectively. One of the most frequent drug-related adverse events was keratopathy observed in nine (32%) patients, leading to therapy discontinuation in only three (11%) of them. Moreover, 22 out of 28 total patients who were treated with at least two administrations achieved an ORR of 50% (CR, 14%; VGPR, 14%; and PR, 22%) with a median PFS and OS of 5 and 11 months, respectively. In conclusion, our multicentric study confirmed efficacy and safety of belantamab-mafodotin in triple-refractory MM patients even in the real-life setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-BCMA | |
| 650 | 4 | |a multi-refractory | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a real life | |
| 650 | 4 | |a refractory | |
| 700 | 1 | |a De Novellis, Danilo |e verfasserin |4 aut | |
| 700 | 1 | |a Trastulli, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Della Pepa, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Fontana, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Carobene, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Di Perna, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a D'Ambrosio, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Romano, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a De Fazio, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Fiumarella, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Gaeta, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Marafioti, Violetta |e verfasserin |4 aut | |
| 700 | 1 | |a Barbato, Serafina |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Rocco, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Serio, Bianca |e verfasserin |4 aut | |
| 700 | 1 | |a Califano, Catello |e verfasserin |4 aut | |
| 700 | 1 | |a Pane, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, Felicetto |e verfasserin |4 aut | |
| 700 | 1 | |a Giudice, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Selleri, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Catalano, Lucio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 12(2022) vom: 16., Seite 1026251 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g day:16 |g pages:1026251 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2022.1026251 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |b 16 |h 1026251 | ||